A double-blind trial of the effects of candicidin on patients with benign prostatic hypertrophy.
62 patients with benign prostatic hypertrophy, leading to bladder outflow obstruction, took part in a randomised double-blind trial. Those patients in the treatment group took 6 capsules of a polyene macrolide, candicidin, each day (300 mg daily dose). Subjective improvement was noted in both the treated and the control group. This improvement was not confirmed by pressure flow analysis of micturition. The results of this trial do not support the view that candicidin is a useful drug in the treatment of benign prostatic hypertrophy.
D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D002174:Candicidin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D008365:Manometry; D008875:Middle Aged; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D012212:Rheology; D001748:Urinary Bladder Neck Obstruction / Q000209:etiology
D000935:Antifungal Agents; D002174:Candicidin